Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Yi Long Wu, Li Zhang, Dong Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih Hsin Yang, Myung Ju Ahn, Johan F. Vansteenkiste, Wu Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S.W. Tan

Research output: Contribution to journalArticlepeer-review

134 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences